The uniformity of nasal spray dose delivery was investigated. Four selected nasal sprays commercially available on the European market were checked for their mass uniformity according to the guidelines of the European Pharmacopoeia and recent draft guidelines of the Food and Drug Administration (FDA). Mass uniformity was also determined with simulation of a patient's use daily, and at 3-and 7-day intervals.
Introduction
Nasal sprays are pharmaceutical preparations which are applied to the nasal cavity to produce local or systemic effects. In contrast to nasal drops, the microbiological burden of the aqueous drug solution or suspension is minimized and dose accuracy improved [I ,2] .
Additionally, nasal sprays are a useful option for many compounds that cannot be administered orally. For these reasons, nasal sprays have become increasingly significant in recent years.
Since highly potent drugs are often given as nasal sprays, control of content uniformity and mass uniformity is of great importance. The authorities demand precise controls on dose accuracy and content or mass uniformity. The European pharmacopoeia gives mandatory guidelines for the control of nasal sprays [3]. The delivered masses of 10 samples have to be determined by difference weighing. A preparation meets the specification if not more than 2 single values deviate by more than 25% and none by more than 35% from the mean value. Recently, the FDA published draft guidelines for nasal sprays [4] which propose a maximum deviation of &I 5% from the target weight for the individual sprays and k10% deviation of the mean weight from the target weight. These guidelines, however, are only recommendations and it remains to be determined whether these limits are realistic and practicable.
The importance of dose accuracy of nasal sprays has already been noted in the literature [5], but little is actually known about it, especially with respect to simulation of patient's use. We aimed to investigate the delivery technique with regard to mass uniformity of some selected nasal sprays available on the European market.
As examples for locally acting preparations, two products containing the anti-allergic drug cromoglicinic acid were chosen (Prep.A, Prep.B).
The effect of the locally acting drug is restricted to the nasal cavity.
Prep.B is a preservative-free, multiple-dose preparation. To comply with the microbiological demands of the Pharmacopoeia, a patented delivery device is used. Studies demonstrating the drug safety of such preservative-free preparations have focused on microbiological safety [6, 7] . Since there is no literature on spray mass uniformity during usage, a comparison to a drug product of similar composition and usage, but with a conventional delivery device was of interest.
To investigate nasal sprays for systemic use, desmopressin nasal sprays were chosen, since there are two comparable products available on the market (Prep.C, Prep. D). Since the drug is poorly absorbed after oral application, the nasal route is used for systemic application [8, 9] . A prerequisite to the safe application of this highly potent drug is accurate mass uniformity, which we tested.
The studies followed the instructions for use of the drug products. In this study the target volumes for 1 puff were 140 pl for the cromoglicinic acid nasal sprays and 100 p1 for the desmopressin nasal sprays.
Experimental

I . Apparatus:
A SCALTEC balance (SCALTEC INSTRUMENTS, Heiligenstadt, Germany) with an accuracy of k 0.01 mg was used.
Materials
Two nasal sprays containing cromoglicinic acid (Preparations A and B) and two nasal sprays containing desmopressin (Preparations C and D) were investigated. The preparations were purchased from German or Austrian pharmacies.
Procedure:
Before measurements were made, the pumps were operated 5 times at 5 s intervals until the spray stream was constant ("priming"), according to the Ph.Eur. guidelines and manufacturers' operating instructions. Subsequently 2 puffs (corresponding to a single dose) were delivered and their masses individually determined by difference weighing of the flasks. To determine the mass uniformity of the different preparations at different intervals of use, this procedure was also carried out at 3-and 7-day intervals (i.e. 2 and 6 days' interruption ), but without repeated priming. . , -
I. Daily use:
After priming, 2 puffs were delivered and the masses of each puff 
Use every 3 days (2 days without actuation):
After priming on the first day, 2 puffs were delivered every 3rd day (without additional priming). The mass of each puff was determined.
As can be seen from The results are shown in Fig. 3 
Investigation of the application devices
We were very much interested in finding out why the dose accuracy of some preparations is strongly effected by the storing period, whereas this was not the case with Prep D to the same extent.
To this end, the application devices of all products were taken apart and studied.
Single doses of all the nasal sprays under consideration here are delivered by a pump system connected to a nasal applicator that also atomizes the liquid.
The pump systems are all similar, with a piston pump with a dosing valve. Scrutiny of the pump systems did not explain why the delivered mass of some of the nasal sprays declined after storage.
In contrast to the pumps, the applicators of the various nasal sprays have one obvious difference, which could be decisive for the maintenance of the delivered mass. The applicator in Prep.D contains an elastic insert which shuts the hollow core of the application system.
This could hinder the decrease by evaporation of the delivered mass of drug solution and permit longer storage periods without actuation.
The lack of this kind of seal might explain the higher weight loss of the other nasal sprays compared to Prep.D. The fact that the values of the second puffs were generally somewhat better than those of the first puffs can be explained by the action of the first puff as a short priming.
These results indicate that nasal sprays, especially Prep.C, should be primed repeatedly when they are not used daily. Prep.B uses a special application system, which allows a preservative-free application of nasal solutions [6,7]. However, as Table 1 shows, there is also some loss of weight with this system during storage; this may be due to evaporation of liquid residues in the upper part of the applicator.
Influence of the degree of filling
The FDA draft guidelines propose testing the influence of the degree of filling on mass uniformity. To this end, 5 full and 5 half-full spray flasks of each product were investigated. The degree of filling was never found to have any significant influence on the uniformity of dose delivery.
lnfluence of the mode of storage
Ten flasks each were stored upright, horizontal and upside down. Surprisingly, the values were slightly higher for flasks whose supply tubes were oriented upward.
Influence of storage with and without closing caps
Five flasks each were stored with and without closing caps.
No significant differences between storing with and without caps were observed for any of the products.
Accordance with the guidelines of the European
Pharmacopeia and the FDA draft guidelines
According to the guidelines of the Ph.Eur., not more than 2 values may deviate more than 25% and none more than 35% from the mean value. Recent draft guidelines from the FDA propose that the weight of the individual sprays should remain within + 15%of the target weight and their mean weight within +I 0% of the target weight.
In our opinion, these specifications should apply not only to the first usage, but throughout the application period.
Upon first usage, all preparations met both the Ph.Eur. guidelines and the FDA draft guidelines. In the case of usage at 7-day intervals, only Prep. C failed to meet these specifications (Tab.2).
Specification
First usage with priming
Ph. Eur. FDA 
Conclusion
The dose accuracy of nasal sprays was tested for four products use. In these cases the operating instructions should be adapted, and the periods of non-usage for re-priming should be shortened. This is also confirmed by the observation that the second puff always showed better values. It can be assumed that the first puff acts as a kind of priming. It is especially important that recommendations not to reprime, as given for a certain preparation, be viewed critically until the dose accuracy during patient's use is demonstrated.
As our results have shown, the deviations from the target weight in the case of interrupted use (simulated patient's usage) are close to the limits or exceed the limits recommended by the FDA in the case of one of the preparations investigated. These guidelines, however, are only a draft and it has yet to be determined whether these guidelines are realistic and practicable. This would require more comprehensive studies of a broad spectrum of preparations to prove the feasibility of these guidelines.
